Navigation Links
IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729
Date:3/12/2009

Test builds on company's suite of tests to evaluate immune function

LENEXA, Kan., March 12 /PRNewswire/ -- IBT Laboratories, a leading clinical-diagnostics and biomedical-research laboratory specializing in immunology and allergy assays, will launch a new diagnostic assay designed to help physicians better understand and manage their patients who have recurrent infections. The company will introduce the Pneumococcal Antibody Avidity Test at the annual meeting of the American Academy of Allergy, Asthma, and Immunology (AAAAI), which opens tomorrow in Washington, DC. The exhibition runs Saturday, March 14 through Monday, March 16, 2009.

According to IBT President, Maureen Loftus, the test builds on the company's suite of assays evaluating immune function. "IBT Laboratories was one of the first laboratories to develop a commercial pneumococcal assay to measure the concentration of antibodies produced in response to the pneumococcal vaccines - today, one of the most-widely prescribed tests used to determine why a patient has recurrent infections. Our new Avidity test now lets the clinician assess the effectiveness of those antibodies. Together, these pneumococcal tests provide more insight into the strengths and weaknesses of a patient's immune system."

IBT offers the widest range of allergy and immunology tests of any laboratory worldwide. The company has an expanded scientific team dedicated specifically to assay development. Its pipeline of new tests slated for launch during 2009 includes traditional and molecular assays based on the latest findings in allergy/immunology research.

Other new tests that the company will feature at AAAAI include the ProGenotyper(TM) Filaggrin Mutation Detection Test, the latest in IBT's expanding menu of molecular assays, and the T-Cell Rx(TM) assay, which adds to IBT's expansive line of tests for adverse drug reactions. The Filaggrin test builds on the company's growing list of tests to investigate skin diseases. It determines whether a patient who presents with the common skin disorders atopic dermatitis or ichthyosis vugaris has a mutation that prevents the skin from working as an effective barrier to allergens and infectious agents. Current research suggests that patients with this mutation may benefit from targeted therapy. The new T-Cell Rx(TM) test assists physicians in assessing patients who have experienced a delayed drug reaction.

IBT will present two scientific posters at the conference:

  • Saturday, 9:45-10:45 am - # 41: T Cell Immunity Assessed by Intracellular Cytokine Analysis Following Stimulation of Whole Blood or PBMCs with Microbial Antigens of Mitogens
  • Sunday, 9:45-10:45 am - # 405: Presence of IgG Anti-IgE Autoantibodies in Chronic Urticaria and Atopic Dermatitis

About IBT Laboratories

A clinical diagnostic and research laboratory specializing in immunology and allergy testing, IBT tests patient samples for physicians, hospitals, and commercial reference labs nationwide. IBT also provides biomarker and immunogenicity testing services to pharmaceutical and biotechnology companies and life-science researchers. Founded in 1983, IBT is privately held and centrally located in Lenexa, Kansas, a suburb of Kansas City.

    Media contact
    Caroline Grossman
    781.771.5579
    Caroline.grossman@gmail.com


'/>"/>
SOURCE IBT Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
6. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
7. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
10. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):